Edgar Filing: Soros Robert

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â PERSEUS SOROS BIOPHARMACEUTICAL FUND LP

2. Date of Event Requiring Statement (Month/Day/Year)
10/04/2007

3. Issuer Name and Ticker or Trading Symbol
MAP Pharmaceuticals, Inc. [MAPP]

(Last)

(First)

(Middle)

888 SEVENTH AVE,Â 30TH FL

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

NEW YORK,Â NYÂ 10106

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Convertible Preferred Stock	Â ⁽⁴⁾	Â ⁽⁴⁾	Common Stock	610,168	$ ⁽⁴⁾	D ⁽¹⁾ ⁽²⁾ ⁽³⁾	Â
Series B Convertible Preferred Stock	Â ⁽⁵⁾	Â ⁽⁵⁾	Common Stock	1,403,766	$ ⁽⁵⁾	D ⁽¹⁾ ⁽²⁾ ⁽³⁾	Â
Series C Convertible Preferred Stock	Â ⁽⁶⁾	Â ⁽⁶⁾	Common Stock	828,147	$ ⁽⁶⁾	D ⁽¹⁾ ⁽²⁾ ⁽³⁾	Â
Series D Convertible Preferred Stock	Â ⁽⁷⁾	Â ⁽⁷⁾	Common Stock	784,683	$ ⁽⁷⁾	D ⁽¹⁾ ⁽²⁾ ⁽³⁾	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
PERSEUS SOROS BIOPHARMACEUTICAL FUND LP 888 SEVENTH AVE 30TH FL NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
PERSEUS SOROS PARTNERS LLC 888 SEVENTH AVE 30TH FL NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
SFM PARTICIPATION LP C/O SOROS FUND MANAGEMENT LLC 888 SEVENTH AVE 31ST FLOOR NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
SFM AH LLC 888 SEVENTH AVENUE 33RD FLOOR NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE 33RD FLOOR NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
SOROS GEORGE 888 SEVENTH AVE 33RD FLR NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
Soros Robert C/O SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â
SOROS JONATHAN T ALLAN C/O SOROS FUND MANAGEMENT LLC 888 SEVENTH AVENUE NEW YORK,Â NYÂ 10106	Â	Â X	Â	Â

Signatures

/s/ Jay Schoenfarber, Assistant General Counsel (8)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Assistant General Counsel (9)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Assistant General Counsel (10)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Assistant General Counsel (11)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Assistant General Counsel (12)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Attorney-in-Fact (13)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Attorney-in-Fact (14)		10/04/2007
^**Signature of Reporting Person		Date
/s/ Jay Schoenfarber, Attorney-in-Fact (15)		10/04/2007
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All of the securities reported herein (the "Shares") are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"). Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"), is the general partner of Perseus-Soros.
(2)	SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), is one of two managing members of Perseus-Soros Partners (see footnote 3). SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC"). Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC. Each of George Soros, Robert Soros and Jonathan Soros may be deemed to have voting power and/or dispositive power over the Shares held for the account of Perseus-Soros.
(3)	Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners") is one of two managing members of Perseus-Soros Partners. Perseuspur, L.L.C., a Delaware limited liability company ("Perseuspur"), is the managing member of Perseus Partners. Mr. Frank Pearl ("Mr. Pearl") individually owns 72.7% of Perseuspur. He also is the sole director and sole shareholder of Rappahannock Investment Company, a Delaware corporation, which in turn owns the remaining 27.3% of Perseuspur. Mr. Pearl in such capacity may be deemed a beneficial owner of the Shares held for the account of Perseus-Soros.
(4)	All of the outstanding shares of the Issuer's Series A Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(5)	All of the outstanding shares of the Issuer's Series B Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(6)	All of the outstanding shares of the Issuer's Series C Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
(7)	All of the outstanding shares of the Issuer's Series D Convertible Preferred Stock will automatically convert into common stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-1.77 reverse stock split, which was effected on October 4, 2007.
Â Remarks: (8)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Ass't.Â GeneralÂ CounselÂ ofÂ SorosÂ FundÂ ManagementÂ LLC,Â asÂ ManagingÂ Member Â ofÂ SFMÂ AHÂ LLC,Â asÂ GeneralÂ PartnerÂ ofÂ SFMÂ Participation,Â L.P.,Â asÂ ManagingÂ MemberÂ ofÂ Perseus-SorosÂ Partners,Â LLC,Â asÂ General Â PartnerÂ ofÂ Perseus-SorosÂ BioPharmaceuticalÂ Fund,Â LP. (9)Â Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Ass't.Â GeneralÂ CounselÂ ofÂ SorosÂ FundÂ ManagementÂ LLC,Â asÂ ManagingÂ Member Â ofÂ SFMÂ AHÂ LLC,Â asÂ GeneralÂ PartnerÂ ofÂ SFMÂ Participation,Â L.P.,Â asÂ ManagingÂ MemberÂ ofÂ Perseus-SorosÂ Partners,Â LLC. (10)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Ass't.Â GeneralÂ CounselÂ ofÂ SorosÂ FundÂ ManagementÂ LLC,Â asÂ ManagingÂ Member Â ofÂ SFMÂ AHÂ LLC,Â asÂ GeneralÂ PartnerÂ ofÂ SFMÂ Participation,Â L.P. (11)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Ass't.Â GeneralÂ CounselÂ ofÂ SorosÂ FundÂ ManagementÂ LLC,Â asÂ ManagingÂ Member Â ofÂ SFMÂ AHÂ LLC. (12)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Ass'tÂ GeneralÂ CounselÂ ofÂ SorosÂ FundÂ ManagementÂ LLC.. (13)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Attorney-in-FactÂ forÂ Mr.Â Soros. (14)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Attorney-in-FactÂ forÂ RobertÂ Soros. (15)Â Â Mr.Â SchoenfarberÂ isÂ signingÂ inÂ hisÂ capacityÂ asÂ Attorney-in-FactÂ forÂ JonathanÂ Soros. ThisÂ FormÂ 3Â isÂ beingÂ filedÂ inÂ twoÂ partsÂ dueÂ toÂ theÂ largeÂ numberÂ ofÂ reportingÂ persons.Â ThisÂ filingÂ isÂ filedÂ byÂ the Â ReportingÂ PersonsÂ listedÂ inÂ FootnotesÂ 1Â andÂ 2Â above.Â AnÂ accompanyingÂ filingÂ isÂ filed,Â onÂ theÂ dateÂ hereof,Â byÂ theÂ Reporting Â PersonsÂ listedÂ inÂ FootnoteÂ 3Â above.Â BothÂ filingsÂ relateÂ toÂ theÂ sameÂ seriesÂ ofÂ transactionsÂ describedÂ above. Exhibits 24.1Â -Â PowerÂ ofÂ AttorneyÂ forÂ Mr.Â Soros 24.2Â -Â PowerÂ ofÂ AttorneyÂ forÂ JonathanÂ Soros 24.3Â -Â PowerÂ ofÂ AttorneyÂ forÂ RobertÂ Soros 99.1

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.